BridgeBio · 2 months ago
US Director, Health Economics & Outcomes Research
United States
Full-time
Remote
Director/Executive
$229K/yr - $260K/yr
8+ years expBridgeBio is a pioneering company focused on groundbreaking advancements in rare diseases and developing life-changing medicines. The US Director of Health Economics & Outcomes Research will be responsible for developing and executing innovative strategies to ensure patient access and commercialization of BridgeBio therapies in the US, collaborating across various functions and engaging with payers and decision-makers.
BiotechnologyHealth CareLife ScienceMedicalPharmaceutical
Responsibilities
Execute on the HEOR plan by designing, developing, and completing HEOR-led studies that support commercialization strategies and demonstrate value to key stakeholders
Lead development of AMCP Dossiers, Budget Impact Models and other economic tools to support the commercialization of BridgeBio therapies
Collaborate with KOLs on study design and authorship to execute HEOR studies and build relationships with Centers of Excellence
Support US field team with engagement with payers and population health decision makers to demonstrate the value of BridgeBio therapies to inform decisions on utilization
Partner with Clinical Development, Evidence Generation and Statistics colleagues on the design and execution of HEOR studies including real world evidence for BridgeBio therapies
Conduct HEOR advisory boards and market research as needed to understand evolving evidence requirements for payers and IDNs in assigned therapeutic areas
Collaborate with Head of HEOR and Market Access colleagues in ICER assessments and responses related to assigned therapeutic areas
Qualification
Required
A Master's Degree in a relevant discipline (e.g., health economics, health services research, medicine, pharmacy, public health, psychometrics, epidemiology, and decision sciences) required
8+ years of relevant experience with an emphasis on the pharmaceutical/medical device industry and/or managed care experience; 6+ years of experience in health economics and outcomes research
Demonstrated understanding of the US and payer policy with a comprehensive understanding of the US healthcare systems and reimbursement processes, and public policy decision-making
Outstanding communication and presentation skills with the ability to present at the executive level and with external thought leaders with the capability to examine and project appropriate details
Well organized with the ability to multitask, prioritize, and manage shifting responsibilities in a small, fast-moving, and entrepreneurial environment
Primarily domestic travel required, expected to be 20-30% of the time
Benefits
401K with 100% employer match on first 3% & 50% on the next 2%
Employee stock purchase program
Pre-tax commuter benefits
Referral program with $2,500 award for hired referrals
Comprehensive health care with 100% premiums covered - no cost to you and dependents
Mental health support via Spring Health (6 therapy sessions & 6 coaching sessions)
Hybrid work model - employees have the autonomy in where and how they do their work
Unlimited flexible paid time off - take the time that you need
Paid parental leave - 4 months for birthing parents & 2 months for non-birthing parents
Flex spending accounts & company-provided group term life & disability
Subsidized lunch via Forkable on days worked from our office
People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility
We provide career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, Spring Health & BetterUp Coaching
We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities
Company
BridgeBio
BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
201-500 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.9BKey Investors
Blue OwlQatar Investment AuthorityKohlberg Kravis Roberts
2026-01-16Post Ipo Debt· $550M
2025-02-25Post Ipo Debt· $500M
2024-03-04Post Ipo Equity· $250M
Leadership Team
Justin To
CEO, Skeletal Dysplasias (QED Therapeutics)
Neil Kumar
CEO and Founder
Recent News
BioWorld Financial Watch
2026-01-17
Company data provided by crunchbase